About Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.
Industry, Sector and Symbol
Trailing P/E Ratio-14.3617021276596
Forward P/E Ratio-9.51
Sales & Book Value
Annual Sales$31.41 million
Price / Sales18.65
Price / CashN/A
Book Value$1.08 per share
Price / Book6.25
Return on Equity-42.52%
Return on Assets-32.70%
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions
What is Arrowhead Pharmaceuticals' stock symbol?
Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."
How were Arrowhead Pharmaceuticals' earnings last quarter?
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) issued its quarterly earnings results on Friday, February, 9th. The biotechnology company reported ($0.18) EPS for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.04. The biotechnology company had revenue of $3.51 million for the quarter, compared to analysts' expectations of $8.71 million. Arrowhead Pharmaceuticals had a negative net margin of 116.17% and a negative return on equity of 42.52%. View Arrowhead Pharmaceuticals' Earnings History.
When will Arrowhead Pharmaceuticals make its next earnings announcement?
Where is Arrowhead Pharmaceuticals' stock going? Where will Arrowhead Pharmaceuticals' stock price be in 2018?
6 brokers have issued 1 year price objectives for Arrowhead Pharmaceuticals' stock. Their forecasts range from $2.00 to $7.00. On average, they anticipate Arrowhead Pharmaceuticals' share price to reach $4.70 in the next year. View Analyst Ratings for Arrowhead Pharmaceuticals.
What are Wall Street analysts saying about Arrowhead Pharmaceuticals stock?
Here are some recent quotes from research analysts about Arrowhead Pharmaceuticals stock:
- 1. Chardan Capital analysts commented, "We believe that Arrowhead is positioned to achieve a number of significant milestones in 2018. The Company spent most of 2017 quietly regrouping following its announcement in November 2016 that it was discontinuing all of its clinical RNAi programs (ARC-520, ARC-521, and ARC-AAT), which use its dynamic polyconjugate (DPC) delivery technology. The decision to discontinue development of these programs was based on the substantial delays that would have occurred in order to further explore the cause of deaths in a non-clinical toxicology study in non-human primates. Arrowhead subsequently reduced its workforce by approximately 30%. In September 2017, the Company unveiled its new proprietary delivery technology they call Targeted RNAi Molecule (TRiM), along with a portfolio of newly named candidates. Arrowhead’s TRiM delivery technology leverages advances in RNA chemistry and targeting, to deliver a payload with increased potency." (2/19/2018)
- 2. Cantor Fitzgerald analysts commented, "Arrowhead reiterated its recently disclosed timeline for returning to clinical development with at least two indications (AAT and HBV) in 1H18." (9/25/2017)
Who are some of Arrowhead Pharmaceuticals' key competitors?
Some companies that are related to Arrowhead Pharmaceuticals include Mallinckrodt (MNK), Cellectis (CLLS), Apellis Pharmaceuticals (APLS), Wave Life Sciences (WVE), Assembly Biosciences (ASMB), Myovant Sciences (MYOV), ARMO BioSciences (ARMO), Revance Therapeutics (RVNC), Genomic Health (GHDX), Audentes Therapeutics (BOLD), Dynavax Technologies (DVAX), Acorda Therapeutics (ACOR), TherapeuticsMD (TXMD), DBV Technologies (DBVT), Zai Lab (ZLAB), Adaptimmune Therapeutics (ADAP), Bavarian Nordic (BVNRY) and Athenex (ATNX).
Who are Arrowhead Pharmaceuticals' key executives?
Arrowhead Pharmaceuticals' management team includes the folowing people:
- Douglass B. Given M.D., Ph.D., Chairman of the Board (Age 64)
- Christopher Richard Anzalone Ph.D., President, Chief Executive Officer, Director (Age 47)
- Kenneth Allen Myszkowski, Chief Financial Officer (Age 50)
- Bruce D. Given M.D., Chief Operating Officer (Age 62)
- Patrick O'Brien, General Counsel (Age 53)
- Michael S. Perry Ph.D., Lead Independent Director (Age 57)
- Mauro Ferrari Ph.D., Independent Director (Age 57)
- Edward W. Frykman, Independent Director (Age 80)
- William D. Waddill, Independent Director (Age 60)
Has Arrowhead Pharmaceuticals been receiving favorable news coverage?
News articles about ARWR stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Arrowhead Pharmaceuticals earned a coverage optimism score of 0.19 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 45.69 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Arrowhead Pharmaceuticals' major shareholders?
Arrowhead Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include OppenheimerFunds Inc. (7.26%), First Manhattan Co. (4.25%), BlackRock Inc. (3.17%), Millennium Management LLC (1.17%), Geode Capital Management LLC (0.69%) and Allianz Asset Management GmbH (0.53%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given and Kenneth Allen Myszkowski. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.
Which institutional investors are selling Arrowhead Pharmaceuticals stock?
ARWR stock was sold by a variety of institutional investors in the last quarter, including ING Groep NV, Millennium Management LLC, BlackRock Inc. and Geode Capital Management LLC. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given and Christopher Richard Anzalone. View Insider Buying and Selling for Arrowhead Pharmaceuticals.
Which institutional investors are buying Arrowhead Pharmaceuticals stock?
ARWR stock was bought by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., First Manhattan Co., Goldman Sachs Group Inc., Alps Advisors Inc., BlueCrest Capital Management Ltd, Acadian Asset Management LLC, Quantitative Investment Management LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Arrowhead Pharmaceuticals.
How do I buy shares of Arrowhead Pharmaceuticals?
Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arrowhead Pharmaceuticals' stock price today?
One share of ARWR stock can currently be purchased for approximately $6.75.
How big of a company is Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals has a market capitalization of $635.28 million and generates $31.41 million in revenue each year. The biotechnology company earns $-34,380,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Arrowhead Pharmaceuticals employs 93 workers across the globe.
How can I contact Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals' mailing address is 225 SOUTH LAKE AVENUE SUITE 1050, PASADENA CA, 91101. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]
MarketBeat Community Rating for Arrowhead Pharmaceuticals (ARWR)MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Hold||Hold|
|Consensus Rating Score: ||2.50||2.50||2.40||2.20|
|Ratings Breakdown: ||0 Sell Rating(s)|
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$4.70||$4.70||$3.17||$2.00|
|Price Target Upside: ||30.37% downside||15.62% downside||10.80% downside||39.39% downside|
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Consensus Price Target History
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Analyst Ratings History
(Data available from 3/23/2016 forward)
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earnings History and Estimates Chart
Arrowhead Pharmaceuticals (NASDAQ ARWR) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/9/2018||Q1 2018||($0.14)||($0.18)||$8.71 million||$3.51 million||View||Listen|
|12/12/2017||Q4 2017||($0.12)||($0.14)||$7.32 million||$8.71 million||View||N/A|
|8/3/2017||Q3 2017||($0.13)||($0.07)||$5.29 million||$9.34 million||View||Listen|
|5/3/2017||Q2 2017||($0.12)||($0.08)||$4.19 million||$8.99 million||View||Listen|
|2/6/2017||Q117||($0.20)||($0.17)||$13.24 million||$4.37 million||View||Listen|
|12/14/2016||Q4 2016||($0.33)||($0.31)||$0.04 million||$0.03 million||View||N/A|
|8/9/2016||Q316||($0.37)||($0.32)||$0.05 million||$39.58 million||View||N/A|
|5/10/2016||Q216||($0.37)||($0.35)||$0.26 million||$0.04 million||View||Listen|
|2/9/2016||Q1||($0.41)||($0.32)||$0.29 million||$0.04 million||View||N/A|
|12/14/2015||Q415||($0.39)||($0.42)||$0.14 million||$0.04 million||View||Listen|
|8/4/2015||Q315||($0.38)||($0.27)||$0.11 million||$0.12 million||View||N/A|
|5/11/2015||Q214||($0.35)||($0.33)||$110.00 million||$43.75 million||View||Listen|
|2/9/2015||Q114||($0.32)||($0.41)||$0.24 million||$0.17 million||View||N/A|
|11/25/2014||Q413||($0.25)||($0.33)||$0.04 million||$0.04 million||View||N/A|
|8/12/2014||Q313||($0.22)||($0.22)||$0.04 million||$0.04 million||View||N/A|
|5/6/2014||Q2 2014||($0.18)||($0.31)||$0.05 million||$0.04 million||View||N/A|
|2/4/2014||Q4||($0.18)||($0.33)||$0.05 million||$0.04 million||View||N/A|
|8/7/2013||Q3 2013||($0.22)||($0.23)||$0.50 million||$0.04 million||View||N/A|
|5/9/2013||Q2 2013||($0.41)||$0.04 million||View||N/A|
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earnings Estimates
2018 EPS Consensus Estimate: ($0.62)
2019 EPS Consensus Estimate: ($0.94)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
No dividend announcements for this company have been tracked by MarketBeat.com
Arrowhead Pharmaceuticals (NASDAQ ARWR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 26.88%
Arrowhead Pharmaceuticals (NASDAQ ARWR) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/15/2018||Christopher Richard Anzalone||CEO||Sell||300,000||$7.43||$2,229,000.00||2,194,789|| |
|3/13/2018||Christopher Richard Anzalone||CEO||Sell||100,000||$7.43||$743,000.00||2,194,789|| |
|3/5/2018||Bruce D Given||COO||Sell||20,000||$6.73||$134,600.00||908,356|| |
|1/1/2018||Bruce D Given||COO||Sell||20,000||$3.69||$73,800.00||948,356|| |
|10/14/2016||Douglas B. Given||Director||Sell||12,000||$6.72||$80,640.00|| |
|8/23/2016||Kenneth Allen Myszkowski||CFO||Sell||6,900||$8.00||$55,200.00||128,789|| |
|8/22/2016||Kenneth Allen Myszkowski||CFO||Sell||13,100||$8.00||$104,800.00||128,789|| |
|12/30/2015||Kenneth Allen Myszkowski||CFO||Sell||23,347||$6.13||$143,117.11||135,000|| |
|10/28/2015||Mauro Ferrari||Director||Buy||400||$7.62||$3,048.00|| |
|10/9/2015||Mauro Ferrari||Director||Buy||1,900||$6.19||$11,761.00|| |
|1/5/2015||David L Lewis||Insider||Sell||15,000||$8.01||$120,150.00|| |
|10/15/2014||Christopher Richard Anzalone||CEO||Buy||16,000||$6.32||$101,120.00|| |
|10/1/2014||Charles Mckenney||Director||Sell||2,500||$14.70||$36,750.00|| |
|9/30/2014||David L Lewis||Insider||Sell||15,000||$15.02||$225,300.00|| |
|9/26/2014||Douglas B Given||Director||Sell||2,000||$15.24||$30,480.00|| |
|6/9/2014||Charles Mckenney||Director||Sell||22,000||$14.32||$315,040.00|| |
|2/12/2014||Kenneth Allen Myszkowski||CFO||Sell||16,000||$18.77||$300,320.00|| |
|2/7/2014||Edward W Frykman||Director||Sell||3,148||$15.98||$50,305.04|| |
Arrowhead Pharmaceuticals (NASDAQ ARWR) News Headlines
Arrowhead Pharmaceuticals (NASDAQ:ARWR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Income Statement, Balance Sheet and Cash Flow Statement
Arrowhead Pharmaceuticals (NASDAQ ARWR) Stock Chart for Friday, March, 23, 2018